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Aim: The aim of the study was in vitro analysis of biological activity of recombinant human beta-defensin-4 (rec-hBD-4). Meth-
ods: hBD-4 cDNA was cloned into pGEX-2T vector, and recombinant plasmid was transformed into E. coli BL21(DE3) cells. 
To purify soluble fusion GST-hBD-4 protein, affinity chromatography was applied. Rec-hBD-4 was cleaved from the fusion 
protein with thrombin, and purified by reverse phase chromatography on Sep-Pack C18. Effects of rec-hBD-4 on proliferation, 
viability, cell cycle distribution, substrate-independent growth, and mobility of cultured human cancer cells of A431, A549, and 
TPC-1 lines were analyzed by direct cell counting technique, MTT assay, flow cytofluorometry, colony forming assay in semi-
soft medium, and wound healing assay. Results: Rec-hBD-4 was expressed in bacterial cells as GST-hBD-4 fusion protein, and 
purified by routine 3-step procedure (affine chromatography on glutathione-agarose, cleavage of fusion protein by thrombin, 
and reverse phase chromatography). Analysis of in vitro activity of rec-hBD-4 toward three human cancer cell lines has dem-
onstrated that the defensin is capable to affect cell behaviour in concentration-dependent manner. In 1–100 nM concentrations 
rec-hBD-4 significantly stimulates cancer cell proliferation and viability, and promotes cell cycle progression through G2/M check-
point, greatly enhances colony-forming activity and mobility of the cells. Treatment of the cells with 500 nM of rec-hBD-4 re-
sulted in opposite effects: significant suppression of cell proliferation and viability, blockage of cell cycle in G1/S checkpoint, 
significant inhibition of cell migration and colony forming activity. Conclusion: Recombinant human beta-defensin-4 is bio-
logically active peptide capable to cause oppositely directed effects toward biologic features of cancer cells in vitro dependent 
on its concentration.
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Human beta-defensins (hBDs), cationic antimi-
crobial peptides and important components of innate 
immunity system in humans, are mainly expressed 
in epithelial cells of different origin and provide first-
line defense of epithelial surfaces from microbial 
challenge. According to modern knowledge, the family 
of hBDs includes at least 30 members most of which 
are indentified by computational analysis and functions 
of which remain unknown [1, 2].
Up to date, the most studied members of beta-
defensin subfamily are hBD-1 and hBD-2, and 
to the lesser extent — hBD-3 and hBD-4. hBD-1 was 
originally isolated from hemofiltrate in 1995 [3], 
and later was found in urogenital and respiratory 
tracts [4]; this defensin is supposed to be consti-
tutively expressed. Three other hBDs are peptides 
with inducible character of expression. hBD-2 was 
isolated from psoriatic skin lesions [5] and later from 
many epithelial tissue types; its expression is shown 
to be regulated by different bacteria and inflamma-
tory factors due to the presence of binding site for 
inflammatory mediator NF-κB in the promoter region 
of hBD-2 gene [6]. hBD-3 and hBD-4 have been 
firstly discovered by screening genomic sequences 
of the Human Genome Project [7, 8]; hBD-3 expres-
sion is induced upon stimulation with interferon-γ via 
STAT binding site in promoter region of hBD-3 gene 
[7]. Also, in 2001 hBD-3 was isolated from psoriatic 
lesions, cloned from keratinocytes and expressed 
as His-Tag-fusion protein in E. coli [9]. hBD-4 gene 
promoter contains no NF-kB or STAT binding sites, 
and its expression is positively regulated with PMA 
and bacteria and is thought to be mediated by protein 
kinase C [8].
All these beta-defensins demonstrate potent anti-
microbial activity against a variety of bacterial patho-
gens, that’s why direct microbial killing is supposed 
to be their main function. However, experimental data 
suggest that defensins are multifunctional molecules 
with a wide spectrum of important biological activities 
and could be involved not only in local immediate anti-
microbial response but also in chemotaxis, modulation 
of inflammatory response, angiogenesis, and wound 
healing [10, 11]. The last process is of special inter-
est. It is shown in a number of studies that expression 
of inducible hBDs is up-regulated in skin lesions after 
injury and these peptides positively regulate kera-
tinocyte proliferation and migration thus promoting 
wound healing [12, 13]. In a number of studies there 
have been documented abilities of hBDs to influence 
many vital cell processes — cell proliferation, viability, 
differentiation, and apoptosis, and it has been shown 
that such effects of hBDs are concentration dependent 
and could be exerted against many cell types, not only 
keratinocytes [14–17]. In a similar manner hBDs may 
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affect growth patterns of tumor cells and may play 
a role in promotion or suppression of human cancer 
cell growth.
In recent years, new insights on possible involve-
ment of hBDs in tumorigenesis have been gained 
[17–27]. hBD-1 is considered a tumor suppressor: 
its expression is absent in prostate cancer and renal 
clear cell carcinoma; down-regulation of hBD-1 ex-
pression contributes to cancer cell survival while its 
induction results in tumor cell death [17, 18]. The 
role of hBD-2 in cancer cell biology is not so evident 
because in different tumor types expression patterns 
of this defensin could differ significantly. In salivary 
gland tumors hBD-2 expression is down-regulated 
[19]; the authors suppose that in salivary gland 
hBD-2 may play antioncogenic functions [19]. Ac-
cording to our data [20, 21], in lung adenocarcinoma 
expression level of hBD-2 correlates with tumor dif-
ferentiation grade, while in vitro this defensin causes 
significant suppression of lung cancer cell growth via 
cell cycle regulation. In oral squamous cell carcinoma 
hBD-2 has been shown to be up-regulated and is sup-
posed to play a pro-oncogenic role [22]. So, functional 
meaning of hBD-2 expression in cancer cells seems 
to depend on histologic type of tumor and on its 
microenvironment. This is true also for hBD-3 which 
is considered as pro-oncogenic molecule in some 
tumors (head and neck cancer, oral carcinoma [23, 
24]) or tumor suppressor in salivary gland tumors [19]. 
Up to date, the role of hBD-4 in tumor cell biology has 
not been analyzed.
In this work we report successful production 
of biologically active recombinant hBD-4 (rec-hBD-4) 
expressed in prokaryotic cells. Analysis of biologic 
activity of this defensin against cultured human can-
cer cells has shown that hBD-4 is capable to affect 
in vitro human tumor cell proliferation and viability, 
migration potential and substrate-independent growth 
in a concentration-dependent manner characteristic 
to other representatives of beta-defensin family.
MATERIALS AND METHODS
Cell lines. Human epidermoid carcinoma A431 cells 
and human lung adenocarcinoma A549 cells were ob-
tained from the Bank of Cell Lines from Human and 
Animal Tissues, R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology, NAS of Ukraine 
(Kyiv, Ukraine). Human papillary thyroid carcinoma 
cell line TPC-1 was kindly provided by Dr. V.M. Push-
karev (V.P. Komissarenko Institute of Endocrinology 
and Metabolism, AMS of Ukraine, Kyiv, Ukraine). The 
cells were cultured in vitro in DMEM culture medium 
supplemented with 10% fetal bovine serum (FBS), 
100 units/mL penicillin G sodium, 100 μg/mL strepto-
mycin sulfate in 5% CO2 atmosphere at 37 °C.
The cloning of hBD-4 and its prokaryotic 
expression. To clone the gene coding for mature 
hBD-4 sequence, total RNA was isolated from 
human lung squamous cell carcinoma sample 
No 5 [27], and hBD-4 cDNA was obtained by re-
verse transcription using a pair of specific primers: 
hBD-4-F: 5`-GTGTTGGATCCGAATTTGAATTG-
GACAGAAT-3`; hBD-4-R: 5`-TCTTGGAATTCT-
CAGGGTTTTGTACGATTCAGTA-3. Primer design 
was based on analysis of NM_080389.2 sequence 
from GenBank database.
HBD-4 cDNA was cloned into pGEX-2T vector 
(GE Healthcare, Sweden). Restriction of plasmids, 
ligation of fragments, bacterial cell transformation 
were performed by standard protocols.
Production and purification of rec-hBD-4. 
Rec-hBD-2 was purified by three-step proce-
dure similarly to rec-hBD-2 [28]. Shortly, E. coli 
BL21(DE3) bacteria transformed with GST-hBD-
4-recombinant plasmid were induced by 1 mM IPTG 
for 6 h, pelleted by centrifugation, resuspended in ly-
sis buffer (50 mМ Tris-HCl, pH 7,6; 250 mМ NaCl; 
1% Triton Х-100 and cocktail of proteases inhibi-
tors), and sonicated using ultrasound disintegrator 
(UD-11 Automatic, Poland). Then cell lysate was 
applied to affine chromatography on glutathione-
agarose column (GE Healthcare, Sweden) with 
following cleavage of the defensin from fusion 
protein by thrombin digestion. hBD-4 peptide was 
further purified by reverse phase chromatography 
on Sep-Pack C18 cartridge (Waters, USA). Pro-
tein concentration was determined by UV absor-
bance at 280 nm using spectrophotometer Nano-
drop-1000 (USA), and purity of the peptide prepa-
ration was analyzed by 7–22% gradient SDS PAAG 
electrophoresis.
Direct cell counting. To study the effect of rec-
hBD-4 on cell proliferation, A431, A549, and TPC-1 cells 
were routinely cultured in 24-well plates (5x104 cells 
per well) to nearly 50% confluence and then treated 
by addition of rec-hBD-4 at various concentrations 
(from 0.1 nM to 1 M) for 48 h in 2.5% FBS medium. 
After the treatment, cells were triply washed with PBS, 
detached with trypsin, and counted in hemocytometer. 
The percentage of dead cells was analyzed using 
trypan blue staining.
MT T assay. To evaluate the effect of rec-
hBD-4 on cell viability, MTT-test has been applied 
[29]. A549, A431, and TPC-1 cells were seeded into 
96-well plates (7x103 cells per well) and incubated with 
rec-hBD-4 for 48 h in medium with 2.5% FBS. Then the 
cells were routinely treated with МТТ (3-[4,5-dimeth-
ylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) 
by standard protocol, and colorimetric reaction was 
evaluated with the use of ELISA reader (Awareness 
Technology Inc, USA) at  = 545.
Flow cytometry analysis. Cells were cultured 
in 10 cm dishes in DMEM culture medium supple-
mented with 10% FBS to 50% confluency, then the me-
dium was replaced by the fresh DMEM supplemented 
with 2.5% FBS, and the cells were treated by addition 
of 1; 10; 100; 250; 500; 750, or 1000 nM rec-hBD-4 for 
48 h. After the treatment, the attached cells were triply 
washed with PBS, harvested by trypsinization, pelleted 
at 4 °C (500 g) for 5 min, washed twice in PBS, and re-
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suspended in 1 ml of hypotonic cell lysis buffer (0.1% 
sodium citrate, 0.1% Triton X-100, 5 mg/ml PI (Sigma, 
USA)). The cells were incubated at RT for 30 min in the 
dark, and cell cycle distribution was analyzed using 
cytometer Becton Dickinson FACS Calibur. The data 
were analyzed with the use of CellQuest software 
package and ModFit LT2.0 program (BDIS, USA) for 
Mac computers.
Antimicrobial activity of rec-hBD-4 was analyzed 
against P. aeruginosa by bacterial growth suppression 
in radial diffusion assay [30]. P. aeruginosa ATCC 
9027 strain was obtained from Ukrainian Collection 
of Microorganisms (D.K. Zabolotny Institute of Micro-
biology and Virology, NAS of Ukraine, Kyiv, Ukraine).
Scratch wound healing assay. An effect of rec-
hBD-4 on mobility of cultured human cancer cells was 
performed by scratch wound healing assay [31]. The 
cells were seeded in 6-well plates (15x104 cells per 
well) and routinely grown till 80% confluence, than 
a scratch was performed using a 20 μl tip, and the 
cells were grown for next 24 h in the presence of 100, 
500 or 1000 nM rec-hBD-4 in serum free medium. 
Then the cell migration into wound area was examined 
using inverted microscope Axioplan (Zeiss, Germany).
Colony forming assay. Substrate independent 
growth was studied by routine procedure [32]. The 
cells were seeded in 3 cm Petri dishes (5х103 cells) 
in the medium containing 0.8% methylcellulose, 2x 
DMEM, 30% FBS and 100; 500, or 1000 nM rec-hBD-4, 
and were cultured in 5% СО2 at 37 °С for 2 weeks. 
Then the colonies were stained with 0.01% neutral red 
in PBS for 30 min, and examined by light microscopy. 
TotalLab program has been used for data calculation.
Statistical analysis. The data are reported as the 
mean ± SD. The statistical significance of diffe rences 
between mean values was assessed by the Stu-
dent’s t-test. Values p < 0.05 were considered statisti-
cally significant.
RESULTS AND DISCUSSION
hBD-4 cloning and prokaryotic expression 
of hBD-4-GST fusion protein. To clone the gene 
encoding mature hBD-4, a predicted 50 amino acid 
protein of 5.9 kDa, hBD-4 cDNA was amplified from 
total RNA isolated from human lung squamous cell 
carcinoma sample No 5 [27]; in this particular tumor 
sample we have registered hBD-4 up-regulation dur-
ing the screening of hBDs expression in human lung 
tumors [27].
For expression of rec-hBD-4 we have used GST-
system for production of recombinant proteins that 
allows protein expression in E. coli strains in a form 
of chimeric proteins fused to GST tag. Both PCR 
product and pGEX-2T vector were purified, digested 
by BamHI and EcoRI restriction endonucleases, li-
gated and the hybrid plasmid was used for subsequent 
transformation of E. coli BL21(DE3) cells. After selec-
tion of colonies, recombinant vectors were analyzed 
by digestion with BamHI and EcoRI endonucleases; 
the result evidenced correct 150 bp insertion (Fig. 1) 
which sequence was shown to correspond to nucleo-
tide sequence of hBD-4 gene by direct DNA sequenc-
ing analysis.
150 bp.
1 2 3 4 5
Fig. 1. Recombinant hBD-4-pGEX-2T construct digested with 
BamH1 and EcoRI endonucleases. Lines 1, 2 — undigested 
plasmid; 3, 4 — recombinant plasmid digested with BamH1 and 
EcoRI endonucleases; line 5 — DNA ladder (Fermentas, USA)
Purification of rec-hBD-4 has been performed 
by routine three-step procedure including affine 
chromatography, proteolysis of fusion protein with 
thrombin and reverse phase chromatography. In brief, 
E. coli BL21DE3 cells transformed with hBD-4-pGEX-
2T construct were induced with 1 mM IPTG for 6 h; 
the cells were collected and disrupted by sonication 
in lysis buffer containing 1% Triton Х-100 and cocktail 
of protease inhibitors. Bacterial cell lysate was clari-
fied by centrifugation, and supernatant was applied 
on glutathione-agarose column (GE Healthcare, 
Sweden); affine chromatography was performed 
by routine procedure according to instructons of the 
manufacturer. Then the fusion protein was treated 
with thrombin (1 U of thrombin per 1 mg of fusion 
protein), and hBD-4 peptide was purified from pro-
teolytic mixture by reverse phase chromatography 
on Sep-Pak С18 column (Water, USA) in acetonitrile 
gradient. Pure hBD-4 fraction was eluted by 70–100% 
acetonitrile, collected, dried in Speed-Vac, analyzed 
by gradient 7–22% SDS-PAGE (Fig. 2) and by in-
hibitory zone test. Rec-hBD-4 was active against P. 
aeruginosa in a dose of 10–15 μM (data not shown). 
In summary, prokaryotic expression of hBD-4 and pu-
rification procedure allowed to purify up to 5 mg of bi-
ologically active rec-hBD-4 from 1 L of IPTG-induced 
bacterial culture.
Effect of rec-hBD-4 on proliferation and viabi-
lity of human cancer cells in vitro. We have analyzed 
an effect of rec-hBD-4 on proliferation and viability 
of three human cancer cell lines — A431 (epidermoid 
carcinoma cells), A549 (lung adenocarcinoma cells), 
and TPC-1 (papillary thyroid cancer cells). As it has 
been shown by direct cell counting technique (Fig. 3), 
rec-hBD-4 exerts a concentration-dependent effect 
on the cell proliferation and stimulates cell proliferation 
in the concentrations from 1 to 100 nM and significantly 
suppresses — in concentrations ≥ 500 nM. Effects 
of hBD-4 were similar in A431 and A549 cells but 
TPC-1 cells seems to be less sunsitive to low nano-
molar concentration of rec-hB44 (Fig. 3). According 
to the data of trypan blue staining, the percentage 
of dead cells in all samples didn’t exceed 4–5% for 
any hBD-4 concentration, so one may conclude that 
in nanomolar concentrations this defensin does not 
cause cell death.
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— rec-hBD-4 (5,9 kDa)
1 2 3 4
Fig. 2. SDS-PAGE analysis of rec-hBD-4 purified by reverse 
phase chromatography on Sep-Pak С18 (Water, USA). 1 — 
molecular weight marker (SM 0661, Fermentas, USA); fractions 
of rec-hBD-4 eluted with 80% CH3CN (2), 70% CH3CN (3), 100% 
CH3CN (4)
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Fig.  3.  A concentrat ion-dependent  ef fect  of  rec-
hBD-4 on the number of viable cultured cells of A431, A549, 
and TPC-1 lines. The number of attached cells was evaluated 
by direct cell counting. Cells were cultured in 24-well plates 
(5x104 cells per well) to nearly 50% confluence, then culture 
medium was replaced with fresh DMEM supplemented with 
2.5% FBS and rec-hBD-4 was added into cell cultivation me-
dium in concentrations of 0.1; 1; 100; 500; 1000 nM, and the 
cells were cultured with rec-hBD-4 for 48 h. The data of three 
independent experiments are presented as the mean ± SD. 
*The difference is significant as compared to appropriate 
control (p < 0.05)
Next, we have analyzed the effect of rec-hBD-4 on vi-
ability of cultured A431, A549 and TPC-1 cells using MTT 
assay. Our data have shown that in low concentrations 
(0.1–100 nM) rec-hBD-2 caused insignificant increase 
of viability of A431, TPC-1 and 549 cells (Fig. 4). In all 
three cell lines treated with 500 nM of rec-hBD-4, a de-
crease of cell viability has been recorded while treatment 
with 1 μM of rec-hBD-4 resulted in significant increase 
of cell viability (Fig. 4). In concentrations more than 
1 μM rec-hBD-4 caused significant suppression of vi-
ability of A431, A549 and TPC-1 cells.
Interestingly, such multimodal effects of rec-
hBD-4 on cell viability were found to be reflected in its 
effects on cell cycle distribution. When A431 cells 
treated with 1 nm — 1 μM rec-hBD-4 were subjected 
to flow cytofluorometry analysis, it has been revealed 
(Fig. 5) that treatment of the cells with 100 nM rec-
hBD-4 resulted in significant stimulation of cell cycle 
in G2/M checkpoint, with 500 nM — in significant 
blockage of cell cycle in G1/S checkpoint; higher 
concentrations of hBD-4 insignificantly suppressed 
cell cycle progression (Fig. 5). Similar results were 
obtained with A549 and TPC-1 cells treated with rec-
hBD-4 (data not shown).
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Fig. 4. A concentration-dependent effect of rec-hBD-4 on viabil-
ity of A431, A549, and TPC-1 cells. Cells were cultured in 96-well 
plates (7x103 cells per well) and incubated with rec-hBD-4 in con-
centrations from 100 pM to 5 M for 48 h in medium supple-
mented with 2.5% FBS. The number of viable cells was evaluated 
by MTT analysis. The data of three independent experiments are 
presented as the mean ± SD
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Fig. 5. Flow cytofluorometry analysis of cell cycle distribu-
tion of A431 cells treated with rec-hBD-4 for 48 h. Cells were 
cultured in 10 cm dishes in culture medium supplemented with 
10% FBS to 50% confluency, then the medium was replaced 
by fresh DMEM supplemented with 2.5% FBS, and cells were 
treated by addition of 1; 10; 100; 250; 500; 750, or 1000 nM rec-
hBD-4 for 48 h. After the treatment, the cells were triply washed 
with PBS, detached with trypsin and subjected to flow cytofluo-
rometry analysis as described in Materials and Methods sec-
tion. The data of two independent experiments are presented 
as the mean ± SD. 
*The difference is significant as compared to appropriate 
control (p < 0.05)
Rec-hBD-4 affects colony-forming activity 
of epithelial cancer cells. We have performed 
colony forming assay to evaluate possible effects 
of rec-hBD-4 on important biological property 
of cancer cells — their ability for substrate in-
dependent growth. In this experiment we have 
used three concentrations of hBD-4 (100, 500, 
1000 nM); addition of the defensin into cell in-
cubation medium significantly affected A431cell 
ability to form colonies in semi-soft medium (Fig. 
6): treatment with 100 nM rec-hBD-4 resulted 
in significant increase of colony numbers com-
pared to control untreated cells (p < 0.05), with 
500 nM — in significant decrease of colony counts 
(p < 0.05), while in the presence of 1 M of the de-
fensin no visible colonies were developed. Similar 
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results were obtained with A549 cells treated with 
rec-hBD-4 (data not shown).
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Fig. 6. Rec-hBD-4 significantly affects colony-forming activity 
of A431 cells. The cells (5х103) were cultured in 3 cm Petri dishes 
(5х103 cells) in the medium containing 0.8% methylcellulose, 2x 
DMEM, 30% FBS in the absence (control cells, A) or presence 
of rec-hBD-4 (100 nM (B), 500 nM (C) or 1 μM (D)). When visible 
colonies developed the plates were stained with 0.01% neutral 
red. The graph represents the numbers of colonies calculated 
with the use of TotalLab program.
*The difference is significant as compared to appropriate 
control (p < 0.05)
Effect of rec-hBD-4 on cancer cell migra-
tion ability. To analyze a possible effect of rec-
hBD-4 on cancer cell mobility, wound healing as-
say has been applied. A431 and TPC-1 cells were 
seeded in 6-well plates (15x104 cells per well) and 
routinely grown till 80% confluence, then a scratch 
was performed using a 20 μL tip, and the cells 
were grown for next 48 h in the presence of 100; 
500 or 1000 nM of rec-hBD-4 in serum free me-
dium. Light microscopy examination has revealed 
(Fig. 7) that 500 nM of rec-hBD-4 significantly sup-
pressed migration of TPC-1 cells while treatment with 
100 or 1000 nM of rec-hBD-4 seems to have no notable 
effect on TPC-1 cell mobility. In A431 cell line defen-
sin moderately affected cell migration: stimulation 
of cell mobility has been detected in cells treated with 
100 nM hBD-4 but 500 or 1000 nM of the defensin 
had insignificant influence on migration of A431 cells 
(Fig. 7).
DISCUSSION
Antimicrobial peptides in general and defensins 
in particular are in spite of scientific interest in recent 
years due to the search for new antibiotics which 
could be used against highly resistant clinical isolates. 
Really, defensins as natural compounds with potent 
antimicrobial activity could be successfully used to kill 
even antibiotic-resistant pathogens [33]. Apart from 
this, defensins may be potentially used in other fields 
of medicine, for example, as anticancer or wound-
healing agents [13, 34].
For experimental purposes defensins are produced 
as synthetic peptides or recombinant molecules ex-
pressed in prokaryotes. In the latest case, to avoid host 
cell autodestruction and to simplify purification proce-
dures, defensins are cloned and expressed in a form 
of fusion proteins containing His-Tag, GST, TrxA, 
or other tags. Such approach has allowed to produce 
biologically active recombinant defensins — hBD-3 [9], 
hBD-2 [29], hBD-26 and -27 [35], and some others. 
Similarly, in present work we have produced soluble 
biologically active recombinant hBD-4 expressed 
in prokaryotic system as GST-hBD-4 fusion peptide 
and for the first time characterized its in vitro activity 
toward human cancer cells.
Up to date, just few articles have described the 
biologic activity of hBD-4 [8, 36]. In these studies 
synthetic peptide has been used; it has been demon-
strated that hBD-4 is active against P. aeruginosa and 
Staphylococcus carnosus, and its antimicrobial activity 
depends on salt concentration; hBD-4 is chemotac-
tic for human blood monocytes at the concentration 
of 10 nM, and its chemotactic activity is independent 
from intracellular calcium mobilization [8]. hBD-4 has 
been supposed to play an important role in defense 
of low respiratory tract against infections, especially 
those caused by P. aeruginosa [36], and in H. pylori 
associated gastritis [37].
b
a
Fig. 7. Wound healing assay in A431 (a) and TPC-1 (b) cells 
treated with 100 nM (B), 500 nM (C) or 1000 nM (D) rec-hBD-4 for 
48 h. A — control untreated cells. The results of typical experi-
ment are presented
Our research has demonstrated for the first time 
that hBD-4 could exert a concentration dependent ef-
fect on biological properties of cultured human cancer 
cells: in low nanomolar concentrations (1–100 nM) rec-
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hBD-4 stimulates cancer cell proli feration and viability, 
promotes cell cycle progression through G2/M check-
point, significantly enhances colony-forming activity 
and mobility of A431, A549, and TPC-1 cells. Treatment 
of cells with 500 nM of rec-hBD-2 resulted in opposite 
effects: significant suppression of cell proliferation and 
viability, blockage of cell cycle in G1/S checkpoint, sig-
nificant inhibition of cell migration and colony forming 
activity. In concentrations more than 5 μM hBD-4 is cy-
totoxic to all studied cell lines. It’s necessary to note 
that biologic effects of rec-hBD-4 were similar, but not 
equal in all three studied cell lines: for example, thyroid 
papillary carcinoma cell migration ability is more sensitive 
to hBD-4 than that of A431 cells.
So, biologic effects of nanomolar concentrations 
of rec-hBD-4 are of bimodal character, unlike to these 
of recombinant hBD-2 described in our earlier publica-
tion [21]. So, hypothetically, at low nanomolar range 
human beta-defensin-4 may play a role of pro-onco-
genic molecule via stimulation of cell proliferation and 
cell malignancy potential, and in high nanomolar range 
hBD-4 could play a role in tumor suppression. It’s of in-
terest to further explore the mechanisms of regulation 
of hBD-4 expression in human epithelial cells, patterns 
of its expression in human carcinoma versus normal 
tissue, and its physiologic content in biologic fluids and 
tissues to understand the possible role of this defensin 
in tumorigenesis.
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